The striking gains in functional capacity and quality of life conferred by baroreflex activation therapy in patients with heart failure, as shown in the pivotal phase 3 clinical trial for this novel intervention, were at least as great in women as in men,JoAnn Lindenfeld, MD, said at the European Society of Cardiology Heart Failure Discoveries virtual meeting. Continue reading →

The report aims to provide a 360-degree view of the market in terms of cutting-edge technology, key developments, drivers, restraints and future trends with impact analysis of these trends on the market for short-term, mid-term and long-term during the forecast period. Further, the report also covers key players profiling with detailed SWOT analysis, financial facts and key developments of products/service from the past three years Continue reading →

PARIS--(BUSINESS WIRE)-- Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX Coronary Bioadaptor System, the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on the Main Arena channel of the PCR e-Course as part of the Late Breaking Trials session by Stefan Verheye, MD, PhD, co-principal investigator and senior interventional cardiologist at the Antwerp Cardiovascular Centre/ZNA Middleheim, Belgium. Twelve-month results for the DynamX Bioadaptor demonstrate: Coronary arteries naturally have the ability to expand with disease progression in order to maintain blood flow to the heart, said Antonio Colombo, MD, co-principal investigator and director, Cardiac Catheterization Laboratory, Columbus Hospital, Milan and Coordinators Cardiac Catheterization Laboratories GVM Group, Care and Research, Lugo (RA), Italy. Continue reading →